WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Synpromics Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
Alloy Therapeutics | November 18, 2022
Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the advancement of Normunity’s immune normalizers, antibody therapies designed to target novel mechanisms that free the body’s normal immunity to fight cancer, which are conceived through a unique biotech-acade...
The World News Monitor | April 08, 2020
• 3 Blue-Chip Biotech Stocks Hitting New Highs. A basket of biotech stocks have surged to new highs in recent weeks, lifting the iShares Nasdaq Biotechnology Index Fund ETF (IBB) within 15 points of 2019 resistance.The stock posted an all-time high at $128 in Tuesday’s session, lifting above 2019 resistance at $122. Price action into the second half of 2019 carved a long series of lower highs and lower lows, dropping the stock to a six-year low....
Germany English News | April 08, 2020
Food Microbiology Testing Market report provides an in-depth analysis of the overall market over a period from 2020-2026. The Food Microbiology Testing Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe. The Food Microbiology Testing Market has been segmented based on different types and application. In order to provide a holistic view of the market current and future market, demand has been included in the report. The Food Microbiology Tes...
Cell and Gene Therapy
Specific Biologics Inc. | December 08, 2021
Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...
Medical, Industry Outlook
Whitepaper
Medical
Research, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE